Physician profile
Aaron G Wesp
NPI 1831169788
$1,962.93
in general payments reported to CMS, 2019-2025
33 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $414 · 2021: $282 · 2022: $58.80 · 2023: $628 · 2024: $129 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $256.47 | 2020-2023 | Trelegy Ellipta, Nucala |
| Novo Nordisk INC | $211.21 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $175.98 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $127.61 | 2019-2025 | |
| Exact Sciences Corporation | $121.93 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $117.35 | 2020-2023 | Trintellix |
| Lilly USA, LLC | $99.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.84 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $74.68 | 2020-2025 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $64.23 | 2021 | |
| Abbott Laboratories | $57.43 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $53.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.53 | 2022-2023 | |
| Inspire Medical Systems, INC. | $43.13 | 2023 | Inspire |
| Insulet Corporation | $38.09 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.98 | 2019-2021 | |
| Esperion Therapeutics, INC. | $35.46 | 2020-2021 | |
| Amgen INC. | $34.72 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Almatica Pharma LLC | $32.82 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.24 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $31.17 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $23.89 | 2022 | |
| Medtronic, INC. | $19.00 | 2025 | Inceptiv |
| Redhill Biopharma INC. | $18.09 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.69 | 2020 | |
| Amarin Pharma, INC. | $17.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.67 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $15.25 | 2023 | Gemtesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.42 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $12.70 | 2023 | Contrave |
| Allergan, INC. | $11.52 | 2020 | |
| Biodelivery Sciences International, INC. | $11.36 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Wesp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.